Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation
Kiran Shekar,Mohd H Abdul-Aziz,Vesa Cheng,Fay Burrows,Hergen Buscher,Young-Jae Cho,Amanda Corley,Arne Diehl,Eileen Gilder,Stephan M Jakob,Hyung-Sook Kim,Bianca J Levkovich,Sung Yoon Lim,Shay McGuinness,Rachael Parke,Vincent Pellegrino,Yok-Ai Que,Claire Reynolds,Sam Rudham,Steven C Wallis,Susan A Welch,David Zacharias,John F Fraser,Jason A Roberts
DOI: https://doi.org/10.1164/rccm.202207-1393OC
2023-03-15
Abstract:Rationale: Data suggest that altered antimicrobial concentrations are likely during extracorporeal membrane oxygenation (ECMO). Objectives: The primary aim of this analysis was to describe the pharmacokinetics (PKs) of antimicrobials in critically ill adult patients receiving ECMO. Our secondary aim was to determine whether current antimicrobial dosing regimens achieve effective and safe exposure. Methods: This study was a prospective, open-labeled, PK study in six ICUs in Australia, New Zealand, South Korea, and Switzerland. Serial blood samples were collected over a single dosing interval during ECMO for 11 antimicrobials. PK parameters were estimated using noncompartmental methods. Adequacy of antimicrobial dosing regimens were evaluated using predefined concentration exposures associated with maximal clinical outcomes and minimal toxicity risks. Measurements and Main Results: We included 993 blood samples from 85 patients. The mean age was 44.7 ± 14.4 years, and 61.2% were male. Thirty-eight patients (44.7%) were receiving renal replacement therapy during the first PK sampling. Large variations (coefficient of variation of ⩾30%) in antimicrobial concentrations were seen leading to more than fivefold variations in all PK parameters across all study antimicrobials. Overall, 70 (56.5%) concentration profiles achieved the predefined target concentration and exposure range. Target attainment rates were not significantly different between modes of ECMO and renal replacement therapy. Poor target attainment was observed across the most frequently used antimicrobials for ECMO recipients, including for oseltamivir (33.3%), piperacillin (44.4%), and vancomycin (27.3%). Conclusions: Antimicrobial PKs were highly variable in critically ill patients receiving ECMO, leading to poor target attainment rates. Clinical trial registered with the Australian New Zealand Clinical Trials Registry (ACTRN12612000559819).